I'll answer the first question on the relationship between the Canadian Partnership Against Cancer and the JODR. It's the intent of the JODR process in phase three, which started some time in the summer, to start to look for synergies and linkages with national initiatives such as the Canadian Partnership Against Cancer. We're looking at potentially doing that through the clinical guidelines action group, which might be a mechanism to bring together national panels of experts, for example. There are other national initiatives under way, such as the National Cancer Institute of Canada economic working group, which we also might want to tap into in terms of national initiatives.
On the relationship with the JODR and the CDR, there is a linkage in terms of the governance. The CDR participates in the steering committee as an observer, so they're linked in that manner as well. Although the CPAC committee will not be deliberating during the interim one-year process, we will have the benefit of having some of the reviews that come out of the CDR for drugs that are within the scope of CDR, or normally would have been within the scope of the CDR.